Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease
- PMID: 9784798
- DOI: 10.1093/ajhp/55.suppl_1.S17
Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease
Abstract
Effective antiplatelet drugs--aspirin, ticlopidine, dipyridamole, and clopidogrel--are reviewed. Aspirin has remained the pharmacologic foundation of stroke prevention, primarily because of its low cost. It has been shown to provide a 22% relative risk reduction of stroke in high-risk patients. Its principal adverse effect is gastrotoxicity. Ticlopidine has been widely used in patients with a high risk of stroke who are sensitive to aspirin or in whom aspirin has failed. It has been associated with a median reduction in adenosine diphosphate-induced platelet aggregation of 70% in about 8-11 days. Ticlopidine has been shown to be superior to aspirin at three years in preventing stroke. The principal adverse effects are diarrhea and rash; there has been a 2.4% occurrence of neutropenia. In a trial comparing aspirin, dipyridamole, and a combination of the two, the risk of stroke was 18% lower with aspirin, 16% lower with dipyridamole, and 37% lower with combination therapy compared with placebo. The adverse-effect profile of dipyridamole has proven to be less problematic than that of aspirin or ticlopidine. In a trial comparing clopidogrel with aspirin, patients receiving clopidogrel had an annual 5.32% risk of ischemic stroke, myocardial infarction, or vascular death compared with 5.83% for patients receiving aspirin. Clopidogrel has been associated with a small occurrence of rash and diarrhea, and gastrointestinal intolerance and hemorrhage were less frequent with clopidogrel than with aspirin. Both aspirin and clopidogrel are associated with a low occurrence of neutropenia. Aspirin, ticlopidine, dipyridamole, and clopidogrel have earned a role in stroke prevention; the different adverse-effect profiles of the drugs will influence the choice of agent.
Similar articles
-
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.JAMA. 2004 Oct 20;292(15):1867-74. doi: 10.1001/jama.292.15.1867. JAMA. 2004. PMID: 15494585 Review.
-
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.J Cardiovasc Pharmacol Ther. 2005 Sep;10(3):153-61. doi: 10.1177/107424840501000302. J Cardiovasc Pharmacol Ther. 2005. PMID: 16211203 Review.
-
Antiplatelet therapy in the prevention of stroke.Drugs. 1991;42 Suppl 5:39-50. doi: 10.2165/00003495-199100425-00007. Drugs. 1991. PMID: 1726215 Review.
-
Clopidogrel for cerebrovascular prevention.Cerebrovasc Dis. 1999 Sep-Oct;9(5):253-60. doi: 10.1159/000015975. Cerebrovasc Dis. 1999. PMID: 10473907 Review.
-
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.Clin Ther. 2008 Feb;30(2):249-59. doi: 10.1016/j.clinthera.2008.02.006. Clin Ther. 2008. PMID: 18343263 Clinical Trial.
Cited by
-
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.J Clin Invest. 2002 Apr;109(8):1031-40. doi: 10.1172/JCI10649. J Clin Invest. 2002. PMID: 11956240 Free PMC article.
-
Chronic constipation in hemiplegic patients.World J Gastroenterol. 2007 Aug 7;13(29):3967-72. doi: 10.3748/wjg.v13.i29.3967. World J Gastroenterol. 2007. PMID: 17663511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical